Celltech won the bidding war for Oxford GlycoSciences this spring, and has announced plans to divest OGS’s proteomics division, which “doesn’t really fit” with the company’s vision for itself, according to a Celltech spokesman.
Craig Venter’s Center for the Advancement of Genomics formed a collaboration with Duke University’s Medical Center. The duo will work together to produce predictive and prognostic data for specific diseases, according to the organizations. They will also look for additional funding from grants and donations.
With plans to move any contract sequencing assignments to its Foster City headquarters, Applied Biosystems shut down its Rockville, Md.-based contract sequencing facility and laid off more than 40 people as a result.
Ciphergen announced the settle-ment of its lawsuit with LumiCyte and Molecular Analytical Systems. Under the terms of the settlement, Ciphergen gains exclusive rights to patents licensed from Baylor College of Medicine for its SELDI-TOF-MS technology.
It’s a three-way: Agilent Technologies, Rosetta Biosoftware, and the Institut Gustave-Roussy joined forces to study gene expression in cancer research.
Proteome Systems teamed up with Iberica for a proteomics and glycomics research effort to study changes associated with osteoarthritis.
Waban Software signed a deal with Partners HealthCare to use its information management system at the Harvard/Partners joint Center for Genetics and Genomics.
A report from the Pittsburgh Technology Council said the region’s biomedical and biotech industry has grown steadily in the last five years, with 79 firms paying nearly 7,000 employees a total of $347 million each year.
The Smithsonian Institute planned a premiere of its new interactive exhibit, “Genome: The Secret of How Life Works” last month. Sponsored by Pfizer and produced by Clear Channel Exhibitions, NHGRI, and Whitehead’s Center for Genome Research, the exhibit will open in Washington, DC, before heading off on a five-year, 15-city tour.
At Cold Spring Harbor Lab’s 68th Symposium in late May, NHGRI’s Francis Collins called on academic scientists to initiate a chemical genomics research thrust as a way to bring genomics further downstream.
Microfluidics firm Nanostream took in $22 million in a late-stage financing round led by AEA Investors and Lilly BioVentures.
Arizona’s Translational Genomics Research Institute will study the genetics of diabetes through a partnership with the city of Phoenix and the Salt River Pima-Maricopa Indian community.
Capital Genomix and the Blan-chette Rockefeller Neurosciences Institute announced plans to build a microarray core facility to be based at the Shady Grove, Md., campus of Johns Hopkins University.
The GeneSweep competition officially ended at last month’s genome symposium at Cold Spring Harbor. Ewan Birney announced the winners, based on gene count and year of entry, using the latest number of genes in the current Ensembl build (24,500) — the closest were Paul Dear of the UK’s Medical Research Council with 27,462 in 2000; Lee Rowen of the Institute for Systems Biology with 25,947 in 2001; and Olivier Jaillon of the French Genoscope with 26,500 in 2002.
Millennium Pharmaceuticals announced plans to lay off 600 people and shut down its facilities in Cambridge, UK, and South San Francisco in a step that the company says will help it focus on drug development.
Ingenium Pharmaceuticals teamed up with Oxagen, a biotech company in the UK. Oxagen will create animal models with certain genetic alterations, and Ingenium will use its genotyping platform to better understand metabolic diseases.